[Augmentation of lymphokine-activated killer (LAK) cell activity by combination of low dose interleukin 2 and several kinds of biological response modifiers (BRMs)].
Ohnishi
H
H
Okuno
K
K
Nakamura
T
T
Nakamura
Y
Y
Yasutomi
M
M
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D014407:Tumor Cells, Cultured / Q000473:pathology
D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D011994:Recombinant Proteins